Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS ...

ADAR1 Capital Management LLC dramatically boosted its holdings in Regeneron Pharmaceuticals by 56.3% during Q4, grabbing 1,361 shares worth nearly $969,000. Several other institutional investors also ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

In this article, we will discuss the 10 Stocks under $10 that will triple.

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Q4 results today: According to market experts, the banking sector is predicted to outperform market estimates, while other segments may face pressure from increased provisioning due to concerns ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...